Tag: litigation

- CMT-SORD program advances; meeting scheduled with the FDA in Q3 2025 to discuss govorestat for the treatment of CMT-SORD

TORONTO, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Mattr Corp. (“Mattr” or the “Company”) (TSX: MATR) reported today its operational and financial results for the three and six months ended June 30, 2025. This press release should be read in conjunction with the Company’s Management Discussion and Analysis (“MD&A”) and interim consolidated financial statements for the six months ended June 30, 2025, which are available on the Company’s website and at www.sedarplus.ca.

VERO BEACH, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Orchid Island Capital, Inc. (the “Company”) (NYSE: ORC) announced today that the Board of Directors of the Company declared a monthly cash dividend for the month of August 2025. The dividend of $0.12 per share will be paid September 29, 2025 to holders of record of the Company’s common stock on August 29, 2025, with an ex-dividend date of August 29, 2025. The Company plans on announcing its next common stock dividend on September 8, 2025.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit.

LOS ANGELES, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Crescent Capital BDC, Inc. (“Crescent BDC” or “Company”) (NASDAQ: CCAP) today reported net investment income of $0.46 per share and net income of $0.41 per share for the quarter ended June 30, 2025. Second quarter net investment income includes the impact of one-time accelerated amortization of $0.02 per share related to deferred financing costs. Net asset value (NAV) per share was $19.55 at June 30, 2025.

ATLANTA, Aug. 13, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Altimmune, Inc. (“Altimmune” or the “Company”) (NASDAQ: ALT). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information, including allegations that the Company consistently touted its inflated expectations for positive topline results from the IMPACT Phase 2b MASH trial, while concealing higher responses in the placebo group, which they knew or should have known would negatively impact the topline results.

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of BellRing Brands, Inc. (“BellRing” or the “Company”) (NYSE: BRBR).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.   

NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Fiserv, Inc. (“Fiserv” or the “Company”)(NYSE: FI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.

Niagara Falls, NY, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Positron Corporation (“Positron” or the “Company”) (OTC: POSC), a leader in molecular imaging technology and services, today announced the sale of four (4) PET-CT 64-slice scanners to a nationally recognized nuclear cardiology group specializing in advanced cardiovascular diagnostics and interventional care.